Abstract:Ibrutinib, an irreversible Bruton tyrosine kinase inhibitor (Btk), is a highly effective drug for treatment a number of B-cell lymphoproliferative disorders and, more recently, graft-versus-host disease. However, a number of potentially adverse events are possible in this therapy, partly related to the non-selective mechanism of the drug’s action. Thus, ibrutinib therapy significantly increases the risks of hemorrhagiccomplications compared to standard chemotherapy, especially when combined with a disagregant … Show more
Set email alert for when this publication receives citations?
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.